TIDMAGL
RNS Number : 3830F
Angle PLC
12 July 2019
For immediate release 12 July 2019
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN, IS
RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION,
DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM THE
UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER
JURISDICTION IN WHICH THE SAME WOULD BE UNLAWFUL.
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY
THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER
THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF
THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS
INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
ANGLE plc ("the Company")
Result of General Meeting and Total Voting Rights
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy
company, is pleased to announce that further to the announcements
of 25 June 2019, the Resolutions put to Shareholders at the General
Meeting of the Company held earlier today, were duly passed.
Completion of the Placing is conditional on Admission of the
Placing Shares becoming effective at 8:00 a.m. on 15 July 2019 or
such later date (being not later than 8:00 a.m. on 12 August 2019)
as the Company, finnCap, WG Partners and Beech Hill may agree.
With effect from Admission of the Placing Shares, the Company
will have 172,754,816 Ordinary Shares in issue, with no shares held
in treasury. Shareholders may use this figure as the denominator by
which they are required to notify their interest in, or change to
their interest in, the Company under the Financial Conduct
Authority's Disclosure Guidance and Transparency Rules.
Capitalised terms not otherwise defined in this announcement
shall have the same meanings ascribed to such terms in the
announcement entitled "Accelerated bookbuild to raise GBP18.0m"
released on 25 June 2019, unless the context requires
otherwise.
For further information ANGLE:
ANGLE plc +44 (0) 1483 343434
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
finnCap Ltd (NOMAD and Joint Broker)
Corporate Finance - Carl Holmes, Simon
Hicks, Max Bullen-Smith
ECM - Alice Lane, Sunila de Silva +44 (0)20 7220 0500
WG Partners (Joint Broker)
Nigel Barnes, Nigel Birks, Andrew Craig,
Chris Lee +44 (0) 203 705 9330
Beech Hill Securities (US Broker)
Thomas Lawrence +1 646 574 3171
FTI Consulting
Simon Conway, Ciara Martin +44 (0) 203 727 1000
Matthew Ventimiglia (US) +1 212 850 5624
For Frequently Used Terms, please see the Company's website on
http://www.angleplc.com/the-parsortix-system/glossary/
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a world-leading liquid biopsy company with
sample-to-answer solutions. ANGLE's proven patent protected
platforms include an epitope-independent circulating tumor cell
(CTC) harvesting technology and a downstream analysis system for
cost effective, highly multiplexed analysis of nucleic acids and
proteins.
ANGLE's cell separation technology is called the Parsortix(TM)
system, and it enables a liquid biopsy (a simple blood test) to be
used to provide the cells of interest to the user in a format
suitable for multiple downstream subsequent analyses. CTCs enable
the complete picture of a cancer to be seen as they allow DNA, RNA
and protein analysis and the live cells harvested can be cultured.
The Parsortix technology is the subject of 24 granted patents in
Europe, the United States, China, Australia, Canada, India, Japan
and Mexico with three extensive families of patents are being
progressed worldwide. The system is based on a microfluidic device
that captures cells based on a combination of their size and
compressibility. The Parsortix system has a CE Mark in Europe for
the indicated use and FDA clearance is in process for the United
States with a 400 subject study in metastatic breast cancer. ANGLE
is seeking to be the first ever FDA cleared CTC harvesting system
and only the third ever FDA cleared liquid biopsy test. ANGLE has
already undertaken two separate 200 subject clinical studies under
a program designed to develop an ovarian cancer pelvic mass triage
test, with the results showing best in class accuracy (ROC-AUC) of
95.1%. The pelvic mass triage assay has undergone further
refinement and optimisation, and is currently in the process of a
clinical verification study.
ANGLE's technology for the multiplex evaluation of proteins and
nucleic acids of all types is called the HyCEAD(TM) Ziplex(R)
platform and is based on a patented flow through array technology.
It provides for low cost, highly multiplexed, rapid and sensitive
capture of targets from a wide variety of sample types. A
proprietary chemistry approach (the HyCEAD method) allows for the
capture and amplification of over 100 biomarkers simultaneously in
a single reaction. The HyCEAD Ziplex system is ideal for measuring
gene expression and other markers directly from Parsortix harvests
and was used in the ovarian cancer pelvic mass triage test to
achieve best in class accuracy (ROC-AUC) of 95.1%.
ANGLE's proprietary technologies can be combined to provide
automated, sample-to-answer results in both centralised laboratory
and point-of-use cartridge formats.
ANGLE has established formal collaborations with world-class
cancer centres and major corporates such as Abbott, Philips and
QIAGEN, and works closely with leading CTC translational research
customers. These Key Opinion Leaders (KOLs) are working to identify
applications with medical utility (clear benefit to patients), and
to secure clinical data that demonstrates that utility in patient
studies. The body of evidence as to the benefits of the Parsortix
system is growing rapidly from our own clinical studies in
metastatic breast cancer and ovarian cancer and also from KOLs with
21 peer-reviewed publications and numerous publicly available
posters, available on our website.
Important Notice
The securities referred to herein have not been, and will not
be, registered under the US Securities Act of 1933, as amended (the
"Securities Act"), or under the applicable securities laws of any
state or other jurisdiction of the United States, and may not be
offered or sold in the United States except pursuant to an
exemption from, or in a transaction not subject to, the
registration requirements of the Securities Act and in compliance
with any applicable securities laws of any state or other
jurisdiction of the United States. There will be no public offer of
securities in the United States.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCGGUUPMUPBUBP
(END) Dow Jones Newswires
July 12, 2019 05:22 ET (09:22 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2024 to May 2024
Angle (LSE:AGL)
Historical Stock Chart
From May 2023 to May 2024